Donald Engelman
From Wikipedia, the free encyclopedia
Donald Max Engelman (born 1941) is Higgins Professor of Biochemistry at Yale University. He is a member of the National Academy of Sciences (1997), fellow of the American Academy of Arts and Sciences,[3] a fellow of the National Institutes of Health, and has been a Guggenheim fellow.[4] He served as the editor of the Annual Review of Biophysics and Biophysical Chemistry (1984–1993).[5]
- Yale University (1970–)
Donald Max Engelman | |
|---|---|
| Alma mater | |
| Occupation | Biochemist, biophysicist, university teacher, scientist |
| Employer |
|
| Awards | |
| Website | medicine |
| Scientific career | |
| Born | 1941 (age 84–85) |
| Education | Reed College, Yale University |
| Awards | Guggenheim fellow |
| Fields | Cancer drugs and treatments |
| Institutions | Yale University |
| Thesis | Solubilization and Aggregation Properties of Membrane Components from Mycoplasma laidlawii (1968) |
| Doctoral students | Mark A. Lemmon[1][2] |
He is a director of the Stryker Corporation.[6] He is involved in the creation of new cancer drugs and treatments.[7] For example, Engelman is involved in research to use peptides to aid in destroying tumors.[8]
Administration, advising, and consulting
Engelman has served as Director of Biological Sciences at Yale, an advisor to the Brookhaven National Laboratory, and a consultant to the Los Alamos National Laboratory.[9] He also served as Acting Dean of Yale College in 1991.[10]
Education
Engelman is a graduate (and trustee[11]) of Reed College receiving his degree in physics. He then earned his Ph.D. in molecular biophysics at Yale University in 1969.[12][13]